Literature DB >> 23860966

Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors.

Dawn A Laney1, Robin L Bennett, Virginia Clarke, Angela Fox, Robert J Hopkin, Jack Johnson, Erin O'Rourke, Katherine Sims, Gerald Walter.   

Abstract

Identification and comprehensive care of individuals who have Fabry disease (FD) requires a multidisciplinary approach inclusive of genetic testing, test interpretation, genetic counseling, long term disease symptom monitoring, treatment recommendations, and coordination of therapy. The purpose of this document is to provide health care professionals with guidelines for testing, care coordination, identification of psychosocial issues, and to facilitate a better understanding of disease treatment expert recommendations for patients with Fabry disease. These recommendations are the opinions of a multicenter working group of genetic counselors, medical geneticists, and other health professionals with expertise in Fabry disease counseling, as well as representatives/founders of the two United States based Fabry disease patient advocacy groups who are themselves affected by Fabry disease. The recommendations are U.S. Preventive Task Force Class III, and they are based on clinical experience, a review of pertinent English-language articles, and reports of expert committees. This document reviews the genetics of Fabry disease, the indications for genetic testing, interpretation of results, psychosocial considerations, and references to professional and patient resources.

Entities:  

Mesh:

Year:  2013        PMID: 23860966     DOI: 10.1007/s10897-013-9613-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  56 in total

Review 1.  Genetic dilemmas and the child's right to an open future.

Authors:  D S Davis
Journal:  Hastings Cent Rep       Date:  1997 Mar-Apr       Impact factor: 2.683

2.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

Authors:  C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

3.  Social-adaptive and psychological functioning of patients affected by Fabry disease.

Authors:  Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta
Journal:  J Inherit Metab Dis       Date:  2010-01-20       Impact factor: 4.982

4.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

5.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

Review 6.  Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

Authors:  Olivier Lidove; Michael L West; Guillem Pintos-Morell; Ricardo Reisin; Kathy Nicholls; Luis E Figuera; Rossella Parini; Luiz R Carvalho; Christoph Kampmann; Gregory M Pastores; Atul Mehta
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

7.  Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Authors:  Stephen Waldek; Manesh R Patel; Maryam Banikazemi; Roberta Lemay; Philip Lee
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

8.  Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease.

Authors:  Natalie Jansen Street; Michael S Yi; Laurie A Bailey; Robert J Hopkin
Journal:  Genet Med       Date:  2006-06       Impact factor: 8.822

9.  Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.

Authors:  Cristina Chimenti; Maurizio Pieroni; Emanuela Morgante; Daniela Antuzzi; Andrea Russo; Matteo Antonio Russo; Attilio Maseri; Andrea Frustaci
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

10.  Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.

Authors:  Anouk C Vedder; Gabor E Linthorst; Gunnar Houge; Johannna E M Groener; Els E Ormel; Berto J Bouma; Johannes M F G Aerts; Asle Hirth; Carla E M Hollak
Journal:  PLoS One       Date:  2007-07-11       Impact factor: 3.240

View more
  24 in total

1.  Elucidating Genetic Counseling Outcomes from the Perspective of Genetic Counselors.

Authors:  Heather A Zierhut; K M Shannon; D L Cragun; S A Cohen
Journal:  J Genet Couns       Date:  2016-01-19       Impact factor: 2.537

Review 2.  Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review.

Authors:  Claudia Regenbogen; Matthias Christoph Braunisch; Christoph Schmaderer; Uwe Heemann
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

3.  The Impact of Fabry Disease on Reproductive Fitness.

Authors:  Dawn A Laney; Virginia Clarke; Allison Foley; Eric W Hall; Scott E Gillespie; Myrl Holida; Morgan Simmons; Alexandrea Wadley
Journal:  JIMD Rep       Date:  2017-03-22

4.  A Retrospective Survey Studying the Impact of Fabry Disease on Pregnancy.

Authors:  Alexandrea Holmes; Dawn Laney
Journal:  JIMD Rep       Date:  2015-02-22

Review 5.  The Psychosocial Impact of Carrying a Debated Variant in the GLA Gene.

Authors:  Sarah Macklin; Dawn Laney; Emily Lisi; Andrea Atherton; Elizabeth Smith
Journal:  J Genet Couns       Date:  2017-08-10       Impact factor: 2.537

6.  Treatment of Depression in Adults with Fabry Disease.

Authors:  Nadia Ali; Scott Gillespie; Dawn Laney
Journal:  JIMD Rep       Date:  2017-04-18

Review 7.  Genetic susceptibility to cerebrovascular disease.

Authors:  David Della-Morte; Francesca Pacifici; Tatjana Rundek
Journal:  Curr Opin Lipidol       Date:  2016-04       Impact factor: 4.776

Review 8.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

9.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

10.  Experiences of Being Heterozygous for Fabry Disease: a Qualitative Study.

Authors:  Charlotte von der Lippe; Jan C Frich; Anna Harris; Kari Nyheim Solbrække
Journal:  J Genet Couns       Date:  2016-03-07       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.